Damora Therapeutics, Inc. (DMRA)
Data as of , from SEC Form 4 filings.
See up to 3 months of DMRA. The 7-day demo opens the 1M and 3M ranges and puts DMRA on your watchlist.
Start 7-day demoLatest DMRA insider trades
Jennifer Jarrett - OfficerOpen-market purchase$253K- Garrett Winslow
About Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
- WALTHAM, MA
- 7
- 2020
- Nasdaq
DMRA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 12,500 | $253K |
| Grant or award | 1 | 30,350 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
DMRA insider transactions (Form 4)
4826 Form 4 filings on record, the earliest from Oct 11, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jennifer Jarrett - Officer | Open-market purchase | Ordinary Shares | 12,500 | $20.23 footnote F2 | $253K | |
| ||||||
 Andrew Cheng - Director | Grant or award | Stock Option (right to buy) | 30,350 | $0.00 | - | |
| Garrett Winslow - Officer | Option exercise | Common Stock | 680 | - footnote F1 | - | |
| Garrett Winslow - Officer | Open-market sale | Common Stock | 245 | $29.98 | $7K | |
| Garrett Winslow - Officer | Option exercise | Restricted Stock Units | 680 | $0.00 | - | |
| ||||||
| Jennifer Jarrett - Officer | Grant or award | Common Stock | 500,000 | $0.00 | - | |
| Jennifer Jarrett - Officer | Grant or award | Stock Option (right to buy) | 1,500,000 | $0.00 | - | |
| Garrett Winslow - Officer | Grant or award | Stock Option (right to buy) | 250,000 | $0.00 | - | |
| Cameron Turtle | Grant or award | Stock Option (right to buy) | 37,313 | $0.00 | - | |
| Michael Landsittel | Grant or award | Stock Option (right to buy) | 37,313 | $0.00 | - | |
| Fairmount Funds Management LLC | Grant or award | Stock Option (right to buy) | 37,313 | $0.00 | - | |
| Christopher W. Cain | Grant or award | Stock Option (right to buy) | 37,313 | $0.00 | - | |
| Julianne Bruno | Grant or award | Stock Option (right to buy) | 37,313 | $0.00 | - | |
| Julianne Bruno | Option exercise | Common Stock | 129,000 | $0.00 | - | |
| Julianne Bruno | Option exercise | Series C Preferred Stock | 129 | $0.00 | - | |
| Fairmount Funds Management LLC | Option exercise | Common Stock | 5,809,000 | $0.00 | - | |
| Fairmount Funds Management LLC | Option exercise | Common Stock | 2,904,000 | $0.00 | - | |
| Fairmount Funds Management LLC | Option exercise | Series C Preferred Stock | 5,809 | $0.00 | - | |
| Fairmount Funds Management LLC | Option exercise | Series C Preferred Stock | 2,904 | $0.00 | - | |
| Sherwin Sattarzadeh - Officer | Grant or award | Common Stock | 190,376 | $0.00 | - | |
| Sherwin Sattarzadeh - Officer | Grant or award | Stock Option (right to buy) | 444,209 | $0.00 | - | |
| L. Becker Hewes - Officer | Grant or award | Common Stock | 264,629 | $0.00 | - | |
| L. Becker Hewes - Officer | Grant or award | Stock Option (right to buy) | 528,603 | $0.00 | - | |
| Hans T. Schambye - Officer | Option exercise | Common Stock | 1,360 | - | - | |
| Hans T. Schambye - Officer | Open-market sale | Common Stock | 700 | $21.38 | $15K | |
| Hans T. Schambye - Officer | Option exercise | Restricted Stock Units | 1,360 | $0.00 | - | |
| Garrett Winslow - Officer | Option exercise | Common Stock | 680 | - | - | |
| Garrett Winslow - Officer | Open-market sale | Common Stock | 255 | $21.38 | $5K | |
| Garrett Winslow - Officer | Option exercise | Restricted Stock Units | 680 | $0.00 | - | |
| Lori Firmani - Officer | Option exercise | Common Stock | 374 | - | - | |
| Lori Firmani - Officer | Open-market sale | Common Stock | 135 | $21.41 | $3K | |
| Lori Firmani - Officer | Option exercise | Restricted Stock Units | 374 | $0.00 | - | |
| Hans T. Schambye - Officer | Option exercise | Common Stock | 1,360 | - | - | |
| Hans T. Schambye - Officer | Open-market sale | Common Stock | 735 | $3.38 | $2K | |
| Hans T. Schambye - Officer | Option exercise | Restricted Stock Units | 1,360 | $0.00 | - | |
| Garrett Winslow - Officer | Option exercise | Common Stock | 680 | - | - | |
| Garrett Winslow - Officer | Open-market sale | Common Stock | 260 | $3.39 | $881 | |
| Garrett Winslow - Officer | Option exercise | Restricted Stock Units | 680 | $0.00 | - | |
| Lori Firmani - Officer | Option exercise | Common Stock | 374 | - | - | |
| Lori Firmani - Officer | Open-market sale | Common Stock | 147 | $3.39 | $498 | |
| Lori Firmani - Officer | Option exercise | Restricted Stock Units | 374 | $0.00 | - | |
| Carl Goldfischer | Grant or award | Stock Option (right to buy) | 1,440 | $0.00 | - | |
| Amy B. Wechsler | Grant or award | Stock Option (right to buy) | 720 | $0.00 | - | |
| Amy B. Wechsler | Grant or award | Stock Option (right to buy) | 480 | $0.00 | - | |
| Garrett Winslow - Officer | Grant or award | Stock Option (right to buy) | 15,600 | $0.00 | - | |
| Lori Firmani - Officer | Grant or award | Stock Option (right to buy) | 13,000 | $0.00 | - | |
| Matthew Kronmiller - Officer | Grant or award | Stock Option (right to buy) | 8,600 | $0.00 | - | |
| Hans T. Schambye - Officer | Grant or award | Stock Option (right to buy) | 44,100 | $0.00 | - | |
Recent DMRA Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Lori Firmani | Officer | 1,800 | $56K | View on EDGAR | |
| - | - | - | - |
DMRA insider trading FAQ
What is the latest insider trade for DMRA?
Damora Therapeutics, Inc. (DMRA) had 2 insider filings in the last 90 days, with the most recent on 28 September 2026. The full record for DMRA runs to 26 Form 4 filings, the earliest from 11 October 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DMRA stock?
1 insider purchase of DMRA was filed in the last 90 days, totaling $253K.
How many insiders are selling DMRA stock?
No insider sales of DMRA were filed in the last 90 days. 7 sales are on record for this company.
Where can I see DMRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DMRA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jennifer Jarrett view on EDGAR
- - Andrew Cheng view on EDGAR
- - Garrett Winslow view on EDGAR
- - Jennifer Jarrett view on EDGAR
- - Garrett Winslow view on EDGAR
- - Cameron Turtle view on EDGAR
- - Michael Landsittel view on EDGAR
- - Fairmount Funds Management LLC view on EDGAR
- - Christopher W. Cain view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where DMRA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DMRA with a 7-day demo
- DMRA on your watchlist
- Every DMRA Form 4 filing on record
- Up to 3 months of DMRA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
